Yourgene Health PLC Yourgene raises IONA® test awareness in Egypt
March 25 2019 - 2:01AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
25 March 2019
Yourgene Health plc
("Yourgene" or the "Company")
Yourgene raises IONA(R) test awareness in Egypt with British
Ambassador
Manchester, UK - 25 March 2019: Yourgene Health (AIM: YGEN), the
international molecular diagnostics group which commercialises
genetic products and services, has held an event in Egypt to raise
awareness of the IONA(R) test, a non-invasive prenatal DNA test for
Down's syndrome, amongst the clinical community.
The event was attended by His Excellency Sir Geoffrey Adams, the
British Ambassador to Egypt; and a number of key customers and
medical professionals. Attendees heard from leading specialists in
the prenatal field, including from the National Research Centre in
Egypt and Ain Shams University's Faculty of Medicine.
British Ambassador in Egypt Sir Geoffrey Adams said: "The
partnership between Egypt and the UK keeps on delivering new
successes for both our countries. Today, British company Yourgene
is bringing its latest technology to support the modernisation of
the Egyptian healthcare system and offer world-class services for
its citizens."
Lyn Rees, CEO of Yourgene, commented: "With a population of
almost 100 million and a desire to offer high quality genetic
analysis, we believe the market in Egypt could become a significant
one for Yourgene going forward. We look forward to continuing to
work with our local partners to deliver safe, fast and highly
accurate prenatal screening solutions to pregnant women across
Egypt."
Yourgene's IONA(R) test estimates the risk of a fetus being
affected with Down's syndrome or other genetic conditions. The test
is performed on a maternal blood sample, containing traces of fetal
DNA, which is then analysed using next generation DNA sequencing
technology. The test is highly accurate and significantly reduces
the number of women who are unnecessarily subjected to risky,
invasive follow up procedures to diagnose Down's syndrome and other
genetic conditions.
For more information, please contact:
Yourgene Health plc Tel: +44 (0)161
Lyn Rees, Chief Executive Officer 667 1053
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@yourgene-health.com
Vigo Communications Tel: +44 (0)20 7390
Ben Simons / Fiona Henson / Antonia Pollock 0238
yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions.
Yourgene Health's first commercialised products are non-invasive
prenatal tests (NIPT) for Down's syndrome and other genetic
disorders, targeting a share of an emerging billion-dollar global
market.
Prenatal screening is an established clinical practice, but
accuracy challenges with traditional methods are driving the need
for NIPT and other DNA-based reproductive health testing solutions.
Yourgene Health's customer-focused products and services support
all types of customer, irrespective of size, geography and market
maturity. Our commercial footprint is already established in the
UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene
Health is aiming to extend its genetic testing offering into
complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore. For more information visit
www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALFFSIVVIFFIA
(END) Dow Jones Newswires
March 25, 2019 03:01 ET (07:01 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Apr 2024 to May 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From May 2023 to May 2024